Evidence map›Paper›PMID 38556531›Full record

ArticleAnnals of hematology2024

Gilteritinib combined with venetoclax and azacitidine for relapsed acute myeloid leukemia cocurrent with pure red cell aplasia after allogeneic hematopoietic stem cell transplantation: a case report.

Jiawen Wang, Han Zhu, Kourong Miao

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jiawen WangThe first affiliated hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Han ZhuThe first affiliated hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China.
Kourong MiaoThe first affiliated hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, 210029, China. kourongmiao@163.com.
Jiangsu Province Hospital · CNNanjing Medical University · CN

Funding

Miao Kourong 81470329
6 · The paper itself

Abstract

Pure red cell aplasia (PRCA) is a rare bone marrow (BM) disorder characterized by ineffective erythropoiesis, reduced reticulocyte count, normocytic anemia, and the absence of erythroid precursors. Here, we present a rare instance of PRCA occurring after ABO-matched allo-HSCT in a refractory/relapsed acute myeloid leukemia (R/R AML) patient. In this case, the patient received a combination treatment of Gilteritinib, Venetoclax, and Azacitidine. Remarkably, this treatment not only reduced myeloblasts but also facilitated the restoration of erythroid hematopoiesis.

Indexed as

Aniline CompoundsBone Marrow DiseasesBridged Bicyclo Compounds, HeterocyclicHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcutePyrazinesRed-Cell Aplasia, PureSulfonamidesAzacitidineHumansAniline CompoundsAzacitidineBridged Bicyclo Compounds, HeterocyclicgilteritinibPyrazinesSulfonamidesvenetoclaxAllogeneic hematopoietic stem cell transplantationPure red cell aplasiaRefractory/relapsed acute myeloid leukemia

Identifiers

PMID38556531
OpenAlexW4393391095

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.